MA50629A - Composés monobactames de chromane pour le traitement d'infections bactériennes - Google Patents

Composés monobactames de chromane pour le traitement d'infections bactériennes

Info

Publication number: MA50629A
Authority: MA; Morocco
Prior art keywords: monobactam; treatment; bacterial infections; chroman compounds; chroman
Prior art date: 2017-10-02

Application number

MA050629A

Other languages

English (en)

Inventor

Tesfaye Biftu

Xianhai Huang

Weiguo Liu

Weidong Pan

Min Park

Alexander Pasternak

Wanying Sun

Haifeng Tang

Yi Zang

Original Assignee

Merck Sharp & Dohme

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2017-10-02

Filing date

2018-09-27

Publication date

2021-03-31

2018-09-27 Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme

2021-03-31 Publication of MA50629A publication Critical patent/MA50629A/fr

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
- A61K31/431—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4425—Pyridinium derivatives, e.g. pralidoxime, pyridostigmine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Organic Chemistry (AREA)
Epidemiology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

MA050629A 2017-10-02 2018-09-27 Composés monobactames de chromane pour le traitement d'infections bactériennes MA50629A (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US201762566779P	2017-10-02	2017-10-02

Publications (1)

Publication Number	Publication Date
MA50629A true MA50629A (fr)	2021-03-31

Family

ID=65994576

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MA050629A MA50629A (fr)	2017-10-02	2018-09-27	Composés monobactames de chromane pour le traitement d'infections bactériennes

Country Status (26)

Country	Link
US (1)	US11433055B2 (fr)
EP (1)	EP3691639B1 (fr)
JP (1)	JP7252948B2 (fr)
KR (1)	KR102425959B1 (fr)
CN (2)	CN111201021B (fr)
AU (1)	AU2018345523B2 (fr)
CA (1)	CA3076022C (fr)
CL (1)	CL2020000860A1 (fr)
CO (1)	CO2020004087A2 (fr)
CR (1)	CR20200148A (fr)
DO (1)	DOP2020000058A (fr)
EA (1)	EA202090604A1 (fr)
ES (1)	ES2968467T3 (fr)
GE (2)	GEAP202215303A (fr)
IL (1)	IL273306B (fr)
JO (1)	JOP20200130B1 (fr)
MA (1)	MA50629A (fr)
MX (1)	MX2020003581A (fr)
NI (1)	NI202000023A (fr)
PE (1)	PE20201256A1 (fr)
PH (1)	PH12020550107A1 (fr)
SA (1)	SA520411571B1 (fr)
SG (1)	SG11202002575UA (fr)
UA (1)	UA126000C2 (fr)
WO (1)	WO2019070492A1 (fr)
ZA (1)	ZA202001721B (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN110156697B (zh) *	2019-05-30	2022-05-06	常州沃腾化工科技有限公司	一种1,2-二甲基-1,4,5,6-四氢嘧啶的合成方法
WO2021257863A1 (fr)	2020-06-19	2021-12-23	Incyte Corporation	Composés de pyrrolotriazine utilisés en tant qu'inhibiteurs de v617f de jak2
US11691971B2 (en)	2020-06-19	2023-07-04	Incyte Corporation	Naphthyridinone compounds as JAK2 V617F inhibitors
BR112023000047A2 (pt)	2020-07-02	2023-03-14	Incyte Corp	Compostos de ureia tricíclicos como inibidores da v617f da jak2
WO2022006456A1 (fr)	2020-07-02	2022-01-06	Incyte Corporation	Composés de pyridone tricyclique en tant qu'inhibiteurs de v617f de jak2
US11661422B2 (en)	2020-08-27	2023-05-30	Incyte Corporation	Tricyclic urea compounds as JAK2 V617F inhibitors
US20240051931A1 (en) *	2020-12-03	2024-02-15	University Of Pittsburgh - Of The Commonwealth System Of Higher Education	Hdac inhibitors
WO2022140231A1 (fr)	2020-12-21	2022-06-30	Incyte Corporation	Composés de déazaguanine utilisés en tant qu'inhibiteurs de v617f de jak2
AR125273A1 (es)	2021-02-25	2023-07-05	Incyte Corp	Lactamas espirocíclicas como inhibidores de jak2 v617f
WO2023082055A1 (fr) *	2021-11-09	2023-05-19	中国医学科学院医药生物技术研究所	COMPOSITION PHARMACEUTIQUE CONTENANT UN COMPOSÉ DE β-LACTAME ET SON UTILISATION
PE20241516A1 (es) *	2021-11-18	2024-07-19	Merck Sharp And Dohme Llc	Compuestos monobactamicos de cromano amidina para tratar las infecciones bacterianas
JP7671398B2 (ja) *	2021-11-18	2025-05-01	メルク・シャープ・アンド・ドーム・エルエルシー	クロマンアミジンモノバクタム抗生物質
KR20240163688A (ko)	2022-03-17	2024-11-19	인사이트 코포레이션	Jak2 v617f 억제제로서의 삼환계 우레아 화합물
WO2024019916A2 (fr) *	2022-07-18	2024-01-25	Merck Sharp & Dohme Llc	Composés monobactame amidine chromane pour le traitement d'infections bactériennes

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4684722A (en)	1986-01-06	1987-08-04	E. R. Squibb & Sons, Inc.	Monosulfactams
US5250691A (en)	1991-09-09	1993-10-05	E. R. Squibb & Sons, Inc.	Heteroaryl derivatives of monocyclic beta-lactam antibiotics
ATE529111T1 (de)	2005-12-07	2011-11-15	Basilea Pharmaceutica Ag	Nützliche monobactam-antibiotika
EP1938822A1 (fr) *	2006-12-21	2008-07-02	Novartis AG	Thérapie combinée pour le traitement des maladies des voies respiratoires
SG189174A1 (en)	2010-10-11	2013-05-31	Biogen Idec Internat Neuroscience Gmbh	Human anti-tau antibodies
DK2646436T3 (en)	2010-11-29	2015-06-29	Pfizer	monobactams
UY34585A (es) *	2012-01-24	2013-09-02	Aicuris Gmbh & Co Kg	Compuestos b-lactámicos sustituidos con amidina, su preparación y uso
BR112014029566A2 (pt)	2012-05-31	2017-07-25	Univ Osaka City	agente terapêutico ou agente profilático para desordens cognitivas, anticorpo monoclonal, anticorpo para proteína tau fosforilada, e, peptídeo
US20140275007A1 (en)	2013-03-14	2014-09-18	Rempex Pharmaceuticals, Inc.	Oxamazin antibiotics
WO2015103583A1 (fr)	2014-01-06	2015-07-09	President And Fellows Of Harvard College	Monobactames et procédés de synthèse et d'utilisation de ces derniers
CN106164072B (zh)	2014-03-24	2019-10-01	诺华股份有限公司	用于治疗细菌感染的单环内酰胺有机化合物
TW202136296A (zh)	2014-06-27	2021-10-01	美商Ｃ２Ｎ醫療診斷有限責任公司	人類化抗-tau抗體
SG10201803472QA (en)	2014-10-31	2018-06-28	Abbvie Sarl	Substituted chromanes and method of use
FR3031423B1 (fr) *	2015-01-06	2018-11-30	Centre National De La Recherche Scientifique	Procede et dispositif de conversion de courant et vehicule comportant un tel dispositif
WO2017106064A1 (fr) *	2015-12-15	2017-06-22	Merck Sharp & Dohme Corp.	Composés de biarylmonobactame et procédés d'utilisation correspondants pour le traitement d'infections bactériennes
CA3016341A1 (fr)	2016-03-07	2017-09-14	Merck Sharp & Dohme Corp.	Composes d'arylmonobactame bicycliques et leurs methodes d'utilisation pour le traitement des infections bacteriennes

2018
- 2018-09-27 MA MA050629A patent/MA50629A/fr unknown
- 2018-09-27 US US16/651,456 patent/US11433055B2/en active Active
- 2018-09-27 GE GEAP202215303A patent/GEAP202215303A/en unknown
- 2018-09-27 CN CN201880064269.2A patent/CN111201021B/zh active Active
- 2018-09-27 WO PCT/US2018/053039 patent/WO2019070492A1/fr not_active Ceased
- 2018-09-27 MX MX2020003581A patent/MX2020003581A/es unknown
- 2018-09-27 AU AU2018345523A patent/AU2018345523B2/en active Active
- 2018-09-27 KR KR1020207012234A patent/KR102425959B1/ko active Active
- 2018-09-27 EP EP18864229.2A patent/EP3691639B1/fr active Active
- 2018-09-27 CN CN202410563311.2A patent/CN118496221A/zh active Pending
- 2018-09-27 ES ES18864229T patent/ES2968467T3/es active Active
- 2018-09-27 JP JP2020518661A patent/JP7252948B2/ja active Active
- 2018-09-27 GE GEAP201815303A patent/GEP20227406B/en unknown
- 2018-09-27 SG SG11202002575UA patent/SG11202002575UA/en unknown
- 2018-09-27 CA CA3076022A patent/CA3076022C/fr active Active
- 2018-09-27 UA UAA202002037A patent/UA126000C2/uk unknown
- 2018-09-27 EA EA202090604A patent/EA202090604A1/ru unknown
- 2018-09-27 PE PE2020000692A patent/PE20201256A1/es unknown
- 2018-09-27 CR CR20200148A patent/CR20200148A/es unknown
2020
- 2020-03-15 IL IL273306A patent/IL273306B/en unknown
- 2020-03-16 DO DO2020000058A patent/DOP2020000058A/es unknown
- 2020-03-18 ZA ZA2020/01721A patent/ZA202001721B/en unknown
- 2020-03-19 SA SA520411571A patent/SA520411571B1/ar unknown
- 2020-03-20 PH PH12020550107A patent/PH12020550107A1/en unknown
- 2020-03-24 NI NI202000023A patent/NI202000023A/es unknown
- 2020-03-31 CO CONC2020/0004087A patent/CO2020004087A2/es unknown
- 2020-03-31 CL CL2020000860A patent/CL2020000860A1/es unknown
- 2020-05-28 JO JOJO/P/2020/0130A patent/JOP20200130B1/ar active

Also Published As

Publication number	Publication date
JOP20200130B1 (ar)	2024-04-18
GEAP202215303A (en)	2022-04-11
DOP2020000058A (es)	2020-09-15
EP3691639A1 (fr)	2020-08-12
CN111201021A (zh)	2020-05-26
NZ762899A (en)	2024-07-26
JP2020536082A (ja)	2020-12-10
IL273306A (en)	2020-04-30
PE20201256A1 (es)	2020-11-16
JOP20200130A1 (ar)	2020-05-28
EA202090604A1 (ru)	2020-10-15
ZA202001721B (en)	2023-02-22
NI202000023A (es)	2020-09-24
JP7252948B2 (ja)	2023-04-05
GEP20227406B (en)	2022-08-25
SG11202002575UA (en)	2020-04-29
ES2968467T3 (es)	2024-05-09
UA126000C2 (uk)	2022-07-27
SA520411571B1 (ar)	2024-08-27
CN118496221A (zh)	2024-08-16
CA3076022C (fr)	2023-01-17
CL2020000860A1 (es)	2020-08-14
AU2018345523A1 (en)	2020-03-26
US20200297702A1 (en)	2020-09-24
CO2020004087A2 (es)	2020-04-24
WO2019070492A1 (fr)	2019-04-11
BR112020006381A2 (pt)	2020-09-24
AU2018345523B2 (en)	2021-10-21
KR20200058520A (ko)	2020-05-27
EP3691639B1 (fr)	2023-11-15
CR20200148A (es)	2020-05-22
BR112020006381A8 (pt)	2023-04-11
CN111201021B (zh)	2024-08-23
CA3076022A1 (fr)	2019-04-11
IL273306B (en)	2022-04-01
MX2020003581A (es)	2020-07-22
US11433055B2 (en)	2022-09-06
PH12020550107A1 (en)	2020-12-07
KR102425959B1 (ko)	2022-07-27
EP3691639A4 (fr)	2021-03-31

Publication	Publication Date	Title
EP3691639A4 (fr)	2021-03-31	Composés monobactames de chromane pour le traitement d'infections bactériennes
MA44083A (fr)	2021-06-02	Composés de biarylmonobactame pour le traitement d'infections bactériennes
EP3600281A4 (fr)	2020-03-18	Traitement d'association pour le traitement ou la prévention de tumeurs
EP3728271A4 (fr)	2021-06-23	Composés macrocycliques pour le traitement de maladie
MA47719A (fr)	2020-01-15	Esketamine pour le traitement de la dépression
MA45539A (fr)	2019-05-08	Dihydropyranopyrimidines pour le traitement d'infections virales
EP3661493A4 (fr)	2021-04-14	Régimes thérapeutiques pour le traitement de l'hémoglobinurie paroxystique nocturne
MA43811A (fr)	2018-11-28	Composés d'arylmonobactame bicycliques et leurs méthodes d'utilisation pour le traitement des infections bactériennes
EP3541408A4 (fr)	2020-06-24	Compositions et méthodes pour le traitement de l'angiogenèse aberrante
EP3374350A4 (fr)	2019-10-02	Composés à base d'hydroxypyridinone et d'hydroxypyrimidinone pour le traitement d'infections bactériennes
EP3405183A4 (fr)	2019-12-11	Dérivés d'adamatane pour le traitement d'une infection à filovirus
MA45845A (fr)	2019-06-12	Traitement d'association pour cancers hématologiques
EP3946357A4 (fr)	2023-04-05	Formulations topiques pour le traitement de neuropathies périphériques
EP3655404A4 (fr)	2021-03-31	Composés et leur utilisation pour le traitement d'infections microbiennes
EP3773221A4 (fr)	2021-09-15	Traitement pour l'hydrocéphalie
MA55218A (fr)	2022-01-12	Eskétamine pour le traitement de la dépression
EP3344325A4 (fr)	2019-05-15	Administration locale de médicaments pour le traitement de l'asthme
EP3443962A4 (fr)	2019-12-25	Dérivé de quinoline pour le traitement du cancer de l'estomac
EP3541379A4 (fr)	2020-05-27	Compositions pour le traitement de l'hypertension
EP3592349A4 (fr)	2021-03-10	Administration de composés antibiotiques pour le traitement d'infections streptococciques, pour le traitement du psoriasis
EP3468554A4 (fr)	2020-01-22	Méthodes pour le traitement de l'ossification hétérotopique
EP3612214A4 (fr)	2021-01-20	Optimisation d'enzymothérapie de remplacement pour le traitement de l'homocystinurie
EP3716966A4 (fr)	2021-08-18	Compositions d'alpha-cétoacides pour le traitement de l'hypoalbuminémie
MA51738A (fr)	2021-05-12	Composés pour le traitement de la douleur
MA45552A (fr)	2019-05-08	Compositions destinées au traitement de l'amylose